



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: J. Prudent et al.

Serial No.:

09/982,667

10/18/01

Group No.: 1637 Examiner:

Jezia Riley

Filed: Entitled:

INVASIVE CLEAVAGE OF NUCLEIC ACIDS

SUPPLEMENTAL INFORMATION **DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date:

Sir or Madam:

The patents and applications listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The following is a listing of these co-owned patents and applications, along with any substantive office actions received (identified by mailing dates). Restriction requirements, notices of missing parts and communications relating to formalities are omitted. Copies of all the office actions listed below (with cited art omitted) are included herewith. The Examiner is requested to make these patents, applications and the associated office actions of official record in this application.

Application Serial No.: 08/599,491

Office Communication mailed: 10/18/96

Office Communication mailed: 08/11/97

• Application Serial No.: 08/682,853

Office Communication mailed: 10/29/97
 Office Communication mailed: 04/23/98
 Office Communication mailed: 09/18/98
 Office Communication mailed: 12/17/98
 Office Communication mailed: 03/23/99

Application Serial No.: 08/756,386

o Office Communication mailed: 09/02/98

Application Serial No.: 08/759,038

Office Communication mailed: 09/19/97
 Office Communication mailed: 03/12/98

Application Serial No.: 08/823,516

o Office Communication mailed: 01/26/98

• Application Serial No.: 09/308,825

Office Communication mailed: 05/09/00
 Office Communication mailed: 09/20/00
 Office Communication mailed: 03/22/01

Application Serial No.: 09/350,309

o Office Communication mailed: 11/22/00

Application Serial No.: 09/350,597

o Office Communication mailed: 10/03/00 o Office Communication mailed: 08/28/01

Application Serial No.: 09/381,212

Office Communication mailed: 10/25/00
 Office Communication mailed: 09/26/01
 Office Communication mailed: 04/0902
 Office Communication mailed: 07/16/02
 Office Communication mailed: 12/03/02
 Office Communication mailed: 12/08/04

Application Serial No.: 09/940,925

o Office Communication mailed: 12/24/02 o Office Communication mailed: 06/17/03 o Office Communication mailed: 01/16/04 o Office Communication mailed: 03/31/04 o Office Communication mailed: 08/09/04 o Office Communication mailed: 10/28/04 Application Serial No.: 09/941,193

o Office Communication mailed: 04/20/04

Application Serial No.: 09/655,378

o Office Communication mailed: 08/15/01

o Office Communication mailed: 04/23/02

o Office Communication mailed: 08/13/02

o Office Communication mailed: 04/24/03

Office Communication mailed: 12/07/04

Application Serial No.: 09/660,924

Office Communication mailed: 07/17/01

o Office Communication mailed: 11/02/01

o Office Communication mailed: 07/29/02

o Office Communication mailed: 05/21/03

o Office Communication mailed: 04/07/04

Application Serial No.: 09/940,244

o Office Communication mailed: 04/10/03

• Application Serial No.: 10/081,806 (6910)

o Office Communication mailed: 12/31/02

o Office Communication mailed: 11/26/03

• Application Serial No.: 09/713,601

o Office Communication mailed: 08/15/02

o Office Communication mailed: 05/23/03

o Office Communication mailed: 12/03/03

• Application Serial No.: 10/033,297

o Office Communication mailed: 01/05/04

o Office Communication mailed: 04/20/04

o Office Communication mailed: 01/11/05

The following applications have not received any substantive office communication to date:

• Application Serial No.: 09/732,622

• Application Serial No.: 10/309,584

Application Serial No.: 10/897,793

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these

citations of official record in this application.

- Hessner et al., Genotyping of Factor V G1691A (Leiden) without the Use of PCR
 by Invasive Cleavage of Oligonucleotide Probes, Clinical Chemistry 46:1051-1056 (2000)
- Lyamichev *et al.*, Experimental and Theoretical Analysis of the Invasive Signal Amplification Reaction, *Biochemistry* 39:9523-9532 (2000)
- Neri *et al.*, Transferring Automation for Large-scale Development and Production of Invader TM SNP Assays, *Progress in Biomedical Optics* 1:117-125 (2000)
- Newlin et al., The Invader Assay: An Alternative To PCR-Based Testing For The
 Detection Of Point Mutations Associated With Venous Thrombosis, Clinical
 Hemostasis Review, 14:10-12 (2000)
- Hall *et al.*, Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction, PNAS 97:8272-8277 (2000)
- Ledford et al., A Multi-Site Study for Detection of the Factor V (Leiden)
 Mutation from Genomic DNA Using a Homogeneous Invader Microtiter Plate
 Fluorescence Resonance Energy Transfer (FRET) Assay, J. Molecular
 Diagnostics 2:97-104 (2000)
- Ma et al., RNA Template-dependent 5' Nuclease Activity of Thermus aquaticus and Thermus thermophilus DNA Polymerases, J. Biol. Chem., 275:24693-24700 (2000)
- Fors *et al.*, Large-scale SNP scoring from unamplified genomic DNA, *Pharmacogenomics* 1(2):219-229 (2000)
- Agarwal et al., Comparison Study For Identifying Promoter Allelic Polymorphism in Interleukin 10 and Tumor Necrosis Factor α Genes, Diagn Mol Pathol 9(3):158-164 (2000)
- Cooksey et al., Evaluation of the Invader Assay, a Linear Signal Amplification
 Method, for Identification of Mutations Associated with Resistance to Rifampin
 and Isoniazid in Mycobacterium tuberculosis, Antimicrobial Agents and
 Chemotherapy, 44:1296-1301 (2000)
- Mein et al., Evaluation of Single Nucleotide Polymorphism Typing with Invader or PCR Amplicons and Its Automation, Genome Research 10:330-343 (2000)

- Lieder, Excitement Builds in Molecular Biology, Advance for Administrators of the Laboratory 50-52 (1999)
- Lieder, Invader Technology Provices Alternative to PCR, Advance for Administrators of the Laboratory, 70-71 (2000)
- Treble et al., Invader ® technology for SNP detection, Gene & Medicine 4:68-72 (2000)
- Kwiatkowski *et al.*, Clinical, Genetic, and Pharmacogenetic Applications of the Invader Assay, *Molecular Diagnosis*, 4:353-364 (1999)
- Check, Labs home in on mutant alleles, College of American Pathologists Today, 1-5 September (1999)
- Griffin *et al.*, Direct genetic analysis by matrix-assisted laser desorption/ionization mass spectrometry, *PNAS* 96:6301-6306 (1999)
- Ryan et al., Non-PCR-Dependent Detection of the Factor V Leiden Mutation From Genomic DNA Using a Homogeneous Invader Microtiter Plate Assay, Molecular Diagnosis, 4:135-144 (1999)
- Kaiser *et al.*, A Comparison of Eubacterial and Archaeal Structure-specific 5'-Exonucleases, *J. Biol. Chem.*, 274:21387-21394 (1999)
- Lyamichev et al., Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes, *Nature Biotech*. 17:292-296-(1999)
- Harrington, The Characterization of the Fen-1 Family of Structure-Specific Endonucleases: Implications For DNA Replication, Recombination, And Repair, Dissertation submitted to the Program in Cancer Biology and the Committee on Graduate Studies of Stanford University (1994)
- DeFrancesco, The Next New Wave in Genome Analysis, *The Scientist*, 12(21):1-3 (1998)

The present application is a continuation of U.S. Patent No. 6,348,314 and is related to U.S. Patent No. 6,090,543. These patents have been the subject of litigation in two separate patent infringement suits: *Third Wave Technologies, Inc. v. EraGen Biosciences, Inc.*, Civil Case No. 3:2002cv00507 (W.D. Wis.) (the "*Third Wave v. EraGen*" litigation), and *Third Wave*

Technologies, Inc. v. Stratagene Corporation, Civil Case No. 3:2004cv00680 (W.D. Wis.)(the "Third Wave v. Stratagene" litigation).

The following documents relate to the *Third Wave v. EraGen* litigation:

- Docket Sheet for Civil Case No. 3:2002cv00507-C (W.D.Wis), filed 09/06/2002, closed on 04/14/2003;
- Complaint, filed 09/06/2002;
- Answer, Affirmative Defenses and Counterclaim, filed 10/07/2002;
- Third Wave Technologies' Reply to Defendant Eragen's Counterclaim, October 28, 2002
- Third Wave Technologies' Motion to Strike Eragen's Affirmative Defenses and Counterclaim of Invalidity, October 28, 2002;
- Defendant's Brief in Opposition to Plaintiff's Motion to Strike Eragen's Affirmative
 Defenses and Counterclaim of Invalidity, November 15, 2002;
- Third Wave Technologies' Reply in Support of Its Motion to Strike Eragen's Affirmative
 Defenses and Counterclaim of Invalidity, November 25, 2002;
- Defendant's Surreply in Opposition to Plaintiff's Motion to Strike Eragen's Affirmative
 Defenses and Counterclaim of Invalidity, November 27, 2002;
- Plaintiff's Response to Defendant's First Set of Interrogatories to Third Wave Technologies, Inc., November 21, 2002;
- Plaintiff's Amended Response to Defendant's First Set of Interrogatories to Third Wave Technologies, Inc., November 21, 2002December 3, 2002;
- Defendant's Rule 26(a)(1) Disclosures; November 4, 2002;
- Defendant's Responses to TWT's Expedited Third Set of Interrogatories (Nos. 15-16),
 January 27, 2003;
- Defendant's Amended Responses to TWT's Expedited Third Set of Interrogatories (Nos. 15-16), March 28, 2003;
- Order on Claims Construction Hearing, March 19, 2003.

If the Examiner would consider any additional pleadings or documents to be helpful or pertinent, Applicants would be pleased to provide them (to the extent possible given Protective

Order constraints).

During the course of the *Third Wave v. EraGen* litigation, EraGen stated an intention to assert that the work reported in the following publication was performed prior to the filing of date of U.S. Patent No. 5,846,717, to which both the '543 and '314 patents claim priority:

Lyamichev, et al., Comparison of the 5' nuclease activities of Taq DNA polymerase and its isolated nuclease domain. Proc Natl Acad Sci USA 96: 6143-6148 (1999)

The following documents relate to the *Third Wave v. Stratagene* litigation, described above.

- Docket Sheet for Civil Case No. 04-C-0680-C (W.D.Wis), filed 09/15/2004;
- Complaint, 09/15/2004;
- Answer, 10/20/2004;
- Amended Answer and Counterclaims, December 30, 2004.

In the *Third Wave v. Stratagene* litigation, Stratagene has asserted that the following new reference may be relevant to the case (copy attached).

• Turchi, et al., Completion of Mammalian Lagging Strand DNA Replication Using Purified Proteins. J. Biol Chem. 268(20):15136-141 (1993)

If the Examiner would consider any additional pleadings or documents to be helpful or pertinent, Applicants would be pleased to provide them (to the extent possible given Protective Order constraints). Stratagene was asked for permission to submit, in this IDS, confidential/restricted documents and information that Stratagene has provided to Third Wave's litigation counsel during the course of the Third Wave v. Stratagene litigation (e.g., responses to interrogatories). Stratagene has denied permission. If the Examiner would like to see any such information, please let us know and we will seek a Court order compelling Stratagene to allow Third Wave to provide this confidential information.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to

PATENT Attorney Docket No. **FORS-06638**

the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

David Casimir

Registration No. 42,395

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105 FORM PTO-1449

U.S. Department of Commerce

(Modified)

Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use Several Sheets If Necessary)

(37 CFR ? 1.98(b))

JAN 3 1 2005

Serial No.: 09/982,667

Applicant: James R. PRUDENT et al.

Filing Date: 10/18/01 Group Art Unit:

U.S. PATENT DOCUMENTS							
Examiner	Cite	Serial / Patent	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
Initials	No	Number					
	1	6,348,314				 	
	2	6,090,543				 	
	3	5,846,717				ļ	
	4	08/599,491					
	5	08/682,853					
	6	08/756,386				ļ <u> </u>	
	7	08/759,038					
	8	08/823,516					
	9	09/308,825					
	10	09/350,309					
	11	09/350,597		<u> </u>			
	12	09/381,212					
	13	09/940,925					
	14	09/941,193					
	15	09/655,378					
	16	09/660,924					
	17	09/940,244					
	18	10/081,806					
	19	09/713,601					
	20	10/033,297					
	21	09/732,622					
	22	10/309,584					
	23	10/891,793					_
							_

Examiner: EXAMINER:

Date Considered:

applicant.

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to



45

Serial No.: 09/982,667 Attorney Docket No.: FORS-06638 FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR ? 1.98(b)) Applicant: James R. PRUDENT et al. Filing Date: 10/18/01 Group Art Unit: OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) Hessner et al., Genotyping of Factor V G1691A (Leiden) without the Use of PCR by Invasive Cleavage of Oligonucleotide Probes, Clinical 24 Chemistry 46:1051-1056 (2000) Lyamichev et al., Experimental and Theoretical Analysis of the Invasive Signal Amplification Reaction, Biochemistry 39:9523-9532 (2000) 25 Neri et al., Transferring Automation for Large-scale Development and Production of Invader TM SNP Assays, Progress in Biomedical Optics 26 Newlin et al., The Invader Assay: An Alternative To PCR-Based Testing For The Detection Of Point Mutations Associated With Venous 27 Thrombosis, Clinical Hemostasis Review, 14:10-12 (2000) Hall et al., Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction, PNAS 97:8272-8277 (2000) 28 Ledford et al., A Multi-Site Study for Detection of the Factor V (Leiden) Mutation from Genomic DNA Using a Homogeneous Invader 29 Microtiter Plate Fluorescence Resonance Energy Transfer (FRET) Assay, J. Molecular Diagnostics 2:97-104 (2000) Ma et al., RNA Template-dependent 5' Nuclease Activity of Thermus aquaticus and Thermus thermophilus DNA Polymerases, J. Biol. Chem., 30 275:24693-24700 (2000) Fors et al., Large-scale SNP scoring from unamplified genomic DNA, Pharmacogenomics 1(2):219-229 (2000) Agarwal et al., Comparison Study For Identifying Promoter Allelic Polymorphism in Interleukin 10 and Tumor Necrosis Factor á Genes, Diagn 32 Mol Pathol 9(3):158-164 (2000) Cooksey et al., Evaluation of the Invader Assay, a Linear Signal Amplification Method, for Identification of Mutations Associated with 33 Resistance to Rifampin and Isoniazid in Mycobacterium tuberculosis, Antimicrobial Agents and Chemotherapy, 44:1296-1301 (2000) Mein et al., Evaluation of Single Nucleotide Polymorphism Typing with Invader or PCR Amplicons and Its Automation, Genome Research 34 10:330-343 (2000 Lieder, Excitement Builds in Molecular Biology, Advance for Administrators of the Laboratory50-52 (1999) 35 Lieder, Invader Technology Provices Alternative to PCR, Advance for Administrators of the Laboratory, 70-71 (2000) 36 Treble et al., Invader ? technology for SNP detection, Gene & Medicine 4:68-72 (2000) 37 Kwiatkowski et al., Clinical, Genetic, and Pharmacogenetic Applications of the Invader Assay, Molecular Diagnosis, 4:353-364 (1999) 38 Check, Labs home in on mutant alleles, College of American Pathologists Today, 1-5 September (1999) 39 Griffin et al., Direct genetic analysis by matrix-assisted laser desorption/ionization mass spectrometry, PNAS 96:6301-6306 (1999) 40 Ryan et al., Non-PCR-Dependent Detection of the Factor V Leiden Mutation From Genomic DNA Using a Homogeneous Invader Microtiter 41 Plate Assay, Molecular Diagnosis, 4:135-144 (1999) Kaiser et al., A Comparison of Eubacterial and Archaeal Structure-specific 5'-Exonucleases, J. Biol. Chem., 274:21387-21394 (1999) 42 Lyamichev et al., Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes, 43 Nature Biotech. 17:292-296-(1999) Harrington, The Characterization of the Fen-1 Family of Structure-Specific Endonucleases: Implications For DNA Replication, Recombination, 44 And Repair, Dissertation submitted to the Program in Cancer Biology and the Committee on Graduate Studies of Stanford University (1994)

Examiner: Date Considered:

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DeFrancesco, The Next New Wave in Genome Analysis, The Scientist, 12(21):1-3 (1998)

Serial No.: 09/982,667 Attorney Docket No.: FORS-06638 FORM PTO-1449 (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR ? 1.98(b)) Applicant: James R. PRUDENT et al. Filing Date: 10/18/01 Group Art Unit: OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) Lyamichev, et al., Comparison of the 5' nuclease activities of Taq DNA polymerase and its isolated nuclease domain. Proc Natl Acad Sci U S A 96: 6143-6148 (1999) Turchi, et al., Completion of Mammalian Lagging Strand DNA Replication Using Purified Proteins. J. Biol Chem. 268(20):15136-141 (1993) 47 Third Wave Technologies, Inc. v. EraGen Biosciences, Inc., Civil Case No. 3:2002cv00507 (W.D. Wis.) (the "Third 48 Wave v. EraGen" litigation) Third Wave Technologies, Inc. v. Stratagene Corporation, Civil Case No. 3:2004cv00680 (W.D. Wis.)(the "Third 49 Wave v. Stratagene" litigation) Docket Sheet for Civil Case No. 3:2002cv00507-C (W.D.Wis), filed 09/06/2002, closed on 04/14/2003 50 Complaint, filed 09/06/2002 51 Answer, Affirmative Defenses and Counterclaim, filed 10/07/2002 52 Third Wave Technologies' Reply to Defendant Eragen's Counterclaim, October 28, 2002 Third Wave Technologies' Motion to Strike Eragen's Affirmative Defenses and Counterclaim of Invalidity, October 54 28, 2002 Defendant's Brief in Opposition to Plaintiff's Motion to Strike Eragen's Affirmative Defenses and Counterclaim of Invalidity, November 15, 2002 Third Wave Technologies' Reply in Support of Its Motion to Strike Eragen's Affirmative Defenses and Counterclaim 56 of Invalidity, November 25, 2002 Defendant's Surreply in Opposition to Plaintiff's Motion to Strike Eragen's Affirmative Defenses and Counterclaim 57 of Invalidity, November 27, 2002 Plaintiff's Response to Defendant's First Set of Interrogatories to Third Wave Technologies, Inc., November 21, 58

Plaintiff's Amended Response to Defendant's First Set of Interrogatories to Third Wave Technologies, Inc.,

Defendant's Amended Responses to TWT's Expedited Third Set of Interrogatories (Nos. 15-16), March 28, 2003

Defendant's Responses to TWT's Expedited Third Set of Interrogatories (Nos. 15-16), January 27, 2003

Date Considered: Examiner: EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next

Amended Answer and Counterclaims, December 30, 2004

Defendant's Rule 26(a)(1) Disclosures; November 4, 2002

Order on Claims Construction Hearing, March 19, 2003

Docket Sheet for Civil Case No. 04-C-0680-C (W.D.Wis), filed 09/15/2004

November 21, 2002December 3, 2002

Complaint, 09/15/2004

Answer, 10/20/2004

communication to applicant.

59

60

62

63

64

65

66